Literature DB >> 2235923

The knowledge and use of screening tests for colorectal and prostate cancer: data from the 1987 National Health Interview Survey.

M L Brown1, A L Potosky, G B Thompson, L G Kessler.   

Abstract

Data based on the 1987 National Health Interview Survey are presented depicting factors associated with the knowledge and use of three tests for the early detection of colorectal and prostate cancer: digital rectal examination, fecal occult blood tests, and flexible sigmoidoscopy. The percentage of the at risk adult population who have ever heard of or had these tests is reported. The association of demographic, personal resource, and health system factors with knowledge of these tests is explored using multivariate logistic regression. Health system factors are most consistently associated with use of the tests and with knowledge. Family income, family size, education, knowledge of cancer early warning signs, and measures of encounters with the health care system are associated both with knowledge of and, independent of knowledge, with use of the tests. Residency in the non-South, being white or female, and having an optimistic attitude about cancer prevention are all factors associated with greater knowledge of the tests, but not greater use among those aware of the tests. Membership in a health maintenance organization is more strongly associated with knowledge and use of fecal occult blood tests than the other tests. No association was found between current smoking status and knowledge of or use of any of the tests.

Entities:  

Mesh:

Year:  1990        PMID: 2235923     DOI: 10.1016/0091-7435(90)90054-n

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  29 in total

1.  Protective effect of faecal occult blood test screening for colorectal cancer: worse prognosis for screening refusers.

Authors:  Y Niv; M Lev-El; G Fraser; G Abuksis; A Tamir
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

2.  Psychosocial risk profiles among black male Veterans Administration patients non-adherent with colorectal cancer screening.

Authors:  Rhonda BeLue; Usha Menon; Anita Y Kinney; Laura A Szalacha
Journal:  Psychooncology       Date:  2010-10-07       Impact factor: 3.894

3.  How sources of health information relate to knowledge and use of cancer screening exams.

Authors:  H I Meissner; A L Potosky; R Convissor
Journal:  J Community Health       Date:  1992-06

4.  The effect of area HMO market share on cancer screening.

Authors:  Laurence C Baker; Kathryn A Phillips; Jennifer S Haas; Su-Ying Liang; Dean Sonneborn
Journal:  Health Serv Res       Date:  2004-12       Impact factor: 3.402

5.  [Early detection of prostate cancer in Germany. A study of a representative random sample of the population].

Authors:  M Sieverding; U Matterne; L Ciccarello; H-J Luboldt
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

6.  Facilitating factors for colorectal cancer screening.

Authors:  Corey H Brouse; Randi L Wolf; Charles E Basch
Journal:  J Cancer Educ       Date:  2008 Jan-Mar       Impact factor: 2.037

7.  Acceptance of flexible sigmoidoscopy as a screening examination for colorectal cancer in an outpatient clinic.

Authors:  S Gölder; W Vogt; H Lichti; H C Rath; A Kullmann; J Schölmerich; F Kullmann
Journal:  Int J Colorectal Dis       Date:  2006-07-04       Impact factor: 2.571

Review 8.  Prostate cancer, screening, and prostate-specific antigen: promise or peril?

Authors:  J D Voss
Journal:  J Gen Intern Med       Date:  1994-08       Impact factor: 5.128

9.  Screening sigmoidoscopy. Factors associated with utilization.

Authors:  S F Lewis; N M Jensen
Journal:  J Gen Intern Med       Date:  1996-09       Impact factor: 5.128

Review 10.  Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning (LGBTQ) populations.

Authors:  Gwendolyn P Quinn; Julian A Sanchez; Steven K Sutton; Susan T Vadaparampil; Giang T Nguyen; B Lee Green; Peter A Kanetsky; Matthew B Schabath
Journal:  CA Cancer J Clin       Date:  2015-07-17       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.